SCHEMBL13633897

SCHEMBL13633897

CCc1nc(-c2ccc(SC)cc2)oc1C

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
MAPT P10636 5/20 0.57
RAB9A P51151 2/20 0.55
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
LMNA P02545 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HTT P42858 1/20 0.47
TP53 P04637 1/20 0.44
MAPK13 O15264 1/20 0.43
GCGR P47871 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
POLB P06746 1/20 0.42
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6504901 0.87 KDM4E (0.55) KDM4ESMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL13503414 0.84 TARBP2 (0.53) KDM4ESMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL12961041 0.81 ALDH1A1 (0.52) KDM4EMAPTRAB9AALDH1A1HSD17B10
SCHEMBL9097470 0.81 ESR1 (0.50) KDM4ESMN1; SMN2MAPTRAB9AHSD17B10
SCHEMBL13179907 0.81 HSD17B10 (0.58) KDM4ESMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL18966853 0.81 RAB9A (0.46) KDM4ESMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL266619 0.81 KDM4E (0.66) KDM4ERAB9AHPGDLMNAMEN1
SCHEMBL13638657 0.79 KDM4E (0.50) KDM4ESMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL12006897 0.78 SMN1; SMN2 (0.71) KDM4ESMN1; SMN2MAPTALDH1A1HSD17B10
SCHEMBL17778918 0.78 SMN1; SMN2 (0.71) KDM4ESMN1; SMN2MAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 KDM4E 4614/4885SMN1; SMN2 2873/4885MAPT 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.